Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has filed a marketing authorisation application (MAA) with the European Medicines Agency (EMA) for Tyverb (lapatinib) in conjunction with paclitaxel.
Subscribe to our email newsletter
Lapatinib is an oral small-molecule inhibitor of the EGFR and ErbB2 (HER2) tyrosine kinase receptors.
The company seeks the approval for Tyverb as a treatment for the patients who are suffering from metastatic breast cancer whose tumours over-express HER2 (ErbB2).
So far, GSK has received approval for Tyverb/Tykerb in 90 countries including the EU, Switzerland, US, Canada, Japan, Australia and countries in South America and Asia.